Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:BYSI NASDAQ:FHTX NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.25+2.5%$2.29$1.09▼$3.40$249.25M0.64781,752 shs239,908 shsBYSIBeyondSpring$1.70+10.1%$1.60$1.18▼$3.44$69.70M0.4124,205 shs76,694 shsFHTXFoghorn Therapeutics$4.30-1.6%$4.70$3.27▼$6.95$251.47M2.97162,778 shs85,313 shsTRDAEntrada Therapeutics$6.60-1.5%$11.28$4.93▼$16.45$255.82M-0.09309,281 shs226,776 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-0.90%+3.79%-9.13%-8.37%+76.61%BYSIBeyondSpring-1.91%+19.38%-7.34%+18.46%-10.93%FHTXFoghorn Therapeutics+3.55%+21.39%-17.70%-24.66%+5.56%TRDAEntrada Therapeutics+2.13%+18.58%-46.95%-44.07%-10.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.25+2.5%$2.29$1.09▼$3.40$249.25M0.64781,752 shs239,908 shsBYSIBeyondSpring$1.70+10.1%$1.60$1.18▼$3.44$69.70M0.4124,205 shs76,694 shsFHTXFoghorn Therapeutics$4.30-1.6%$4.70$3.27▼$6.95$251.47M2.97162,778 shs85,313 shsTRDAEntrada Therapeutics$6.60-1.5%$11.28$4.93▼$16.45$255.82M-0.09309,281 shs226,776 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-0.90%+3.79%-9.13%-8.37%+76.61%BYSIBeyondSpring-1.91%+19.38%-7.34%+18.46%-10.93%FHTXFoghorn Therapeutics+3.55%+21.39%-17.70%-24.66%+5.56%TRDAEntrada Therapeutics+2.13%+18.58%-46.95%-44.07%-10.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.6361.47% UpsideBYSIBeyondSpring 1.00SellN/AN/AFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43165.66% UpsideTRDAEntrada Therapeutics 2.50Moderate Buy$18.25176.52% UpsideCurrent Analyst Ratings BreakdownLatest BYSI, ALEC, FHTX, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026TRDAEntrada Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.005/8/2026TRDAEntrada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.004/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026ALECAlector Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/6/2026TRDAEntrada Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $23.004/1/2026TRDAEntrada Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/27/2026TRDAEntrada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/12/2026FHTXFoghorn Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$18.42M13.53N/AN/A$0.09 per share24.94BYSIBeyondSpringN/AN/A$0.12 per share13.82($0.74) per shareN/AFHTXFoghorn Therapeutics$28.22M8.95N/AN/A($1.30) per share-3.31TRDAEntrada Therapeutics$25.42M10.08N/AN/A$6.98 per share0.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)BYSIBeyondSpring-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)FHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)Latest BYSI, ALEC, FHTX, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/A3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25BYSIBeyondSpringN/A1.091.09FHTXFoghorn TherapeuticsN/A2.922.92TRDAEntrada TherapeuticsN/A13.9013.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%BYSIBeyondSpring40.29%FHTXFoghorn Therapeutics61.55%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%BYSIBeyondSpring29.31%FHTXFoghorn Therapeutics7.58%TRDAEntrada Therapeutics9.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionableTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableBYSI, ALEC, FHTX, and TRDA HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 26 at 5:33 PM | globenewswire.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 21, 2026 | prnewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 21, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 19, 2026 | globenewswire.comINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCMay 18, 2026 | globenewswire.comTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the ...May 18, 2026 | caledonianrecord.comCTRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 14, 2026 | prnewswire.comHC Wainwright Has Positive Estimate for TRDA Q2 EarningsMay 12, 2026 | marketbeat.comEntrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 11, 2026 | globenewswire.comHC Wainwright & Co. downgrades Entrada Therapeutics (TRDA)May 9, 2026 | msn.comEntrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileMay 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM)May 9, 2026 | theglobeandmail.comEntrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.11 EPSMay 7, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), Edgewise Therapeutics (EWTX) and Elevance Health (ELV)May 7, 2026 | theglobeandmail.comEntrada plunges after early-stage trial data for Duchenne therapyMay 7, 2026 | msn.comEntrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's WhyMay 7, 2026 | benzinga.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comEntrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month High on Earnings BeatMay 7, 2026 | marketbeat.comEntrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial PositionMay 7, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBYSI, ALEC, FHTX, and TRDA Company DescriptionsAlector NASDAQ:ALEC$2.24 +0.06 (+2.51%) As of 01:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.BeyondSpring NASDAQ:BYSI$1.70 +0.16 (+10.06%) As of 01:46 PM Eastern This is a fair market value price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Foghorn Therapeutics NASDAQ:FHTX$4.30 -0.07 (-1.56%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Entrada Therapeutics NASDAQ:TRDA$6.60 -0.10 (-1.49%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Micron’s $1 Trillion Memory Melt-Up Modine’s $4B AI Coup Freezes Out the Competition What Investors Need to Know About TSMC's Hefty 17% Dividend Increase AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
